Just don't let life science fundamentals tank even more, or RayJa's rosy outlook might wilt. HR, on the other hand, got a bit too cocky after its new strategic plan wowed the crowd, outperforming DOC by 18%. But now it's prancing around at full NAV, and everyone's betting big on it. RayJa's calling BS—HR's plan to juice NOI margins by 200 bps will take forever, and those $1B in dilutive sales might drag into 2026, messing with 2027 earnings. Unless HR pulls a rabbit out of its hat or starts selling off assets like hotcakes, RayJa's not buying what they're selling. TransMedics Group What happened? On Tuesday, Evercore initiated coverage on TransMedics Group Inc (NASDAQ:TMDX) at Outperform with a $155 price target. * TLDR : Evercore backs OCS+NOP despite cost. Aims for growth, high margins by 2028. What's the full story?